XML 37 R24.htm IDEA: XBRL DOCUMENT
v3.21.1

Balance Sheet Components (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract] |
Schedule of Cash and Cash Equivalents | Cash and cash equivalents consisted of the following (in thousands):
|  | March 31, 2021 |  |  | December 31, 2020 |
Cash |  | $ | 100,735 |  |  | $ | 88,046 |
Commercial paper |  |  | 41,419 |  |  |  | — |
Corporate bonds |  |  | 9,085 |  |  |  | — |
Money market funds |  |  | 282,269 |  |  |  | 590,347 |
Total cash and cash equivalents |  | $ | 433,508 |  |  | $ | 678,393 |
Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments | The Company’s investments consist of available-for-sale debt investments and marketable equity investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major investments type are summarized in the tables below (in thousands):
|  | March 31, 2021 |
|  | Amortized Cost |  |  | Gross Unrealized Holding Gains |  |  | Gross Unrealized Holding Losses |  |  | Fair Value |
Corporate bonds |  | $ | 75,503 |  |  | $ | 4 |  |  | $ | (54 | ) |  | $ | 75,453 |
Commercial paper |  |  | 59,536 |  |  |  | 4 |  |  |  | (1 | ) |  |  | 59,539 |
U.S. government bonds |  |  | 30,060 |  |  |  | 2 |  |  |  | (3 | ) |  |  | 30,059 |
Agency bonds |  |  | 14,349 |  |  |  | 1 |  |  |  | (3 | ) |  |  | 14,347 |
Asset-backed securities |  |  | 12,573 |  |  |  | — |  |  |  | (4 | ) |  |  | 12,569 |
Foreign government bonds |  |  | 12,195 |  |  |  | 1 |  |  |  | (2 | ) |  |  | 12,194 |
Equity investments |  |  | 125 |  |  |  | 117 |  |  |  | — |  |  |  | 242 |
Total investments |  | $ | 204,341 |  |  | $ | 129 |  |  | $ | (67 | ) |  | $ | 204,403 |
|  | December 31, 2020 |
|  | Amortized Cost |  |  | Gross Unrealized Holding Gains |  |  | Gross Unrealized Holding Losses |  |  | Fair Value |
Bond and mutual funds |  | $ | 8,147 |  |  | $ | — |  |  | $ | (3 | ) |  | $ | 8,144 |
Equity investments |  |  | 125 |  |  |  | 119 |  |  |  | — |  |  |  | 244 |
Total investments |  | $ | 8,272 |  |  | $ | 119 |  |  | $ | (3 | ) |  | $ | 8,388 |
Schedule of Inventory | Inventories consisted of the following (in thousands):
|  | March 31, 2021 |  |  | December 31, 2020 |
Raw materials |  | $ | 3,308 |  |  | $ | 2,303 |
Work-in-progress |  |  | 9,661 |  |  |  | 8,114 |
Finished goods |  |  | 7,795 |  |  |  | 6,113 |
Total inventories |  | $ | 20,764 |  |  | $ | 16,530 |
Schedule of Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets consisted of the following (in thousands):
|  | March 31, 2021 |  |  | December 31, 2020 |
Unbilled contract assets |  | $ | 7,721 |  |  | $ | 2,147 |
Deferred revenues from associated contracts |  |  | (3,691 | ) |  |  | (2,147 | )
Net unbilled contract assets |  |  | 4,030 |  |  |  | — |
Prepaid assets |  |  | 9,602 |  |  |  | 8,353 |
Other current assets |  |  | 2,523 |  |  |  | 1,807 |
Total prepaid expenses and other current assets |  | $ | 16,155 |  |  | $ | 10,160 |
Schedule of Property and Equipment | Property and equipment consisted of the following (in thousands):
|  | March 31, 2021 |  |  | December 31, 2020 |
Leasehold improvements |  | $ | 102,265 |  |  | $ | 102,006 |
Laboratory equipment |  |  | 18,541 |  |  |  | 18,143 |
Machinery |  |  | 8,231 |  |  |  | 8,312 |
Computer equipment |  |  | 9,107 |  |  |  | 9,545 |
Furniture and fixtures |  |  | 6,195 |  |  |  | 6,128 |
Construction in progress |  |  | 228 |  |  |  | 760 |
Total property and equipment |  | $ | 144,567 |  |  | $ | 144,894 |
Less: accumulated depreciation |  |  | (113,634 | ) |  |  | (111,247 | )
Property and equipment, net |  | $ | 30,933 |  |  | $ | 33,647 |
Schedule of Accrued and Other Current Liabilities | Accrued and other current liabilities consisted of the following (in thousands):
|  | March 31, 2021 |  |  | December 31, 2020 |
Preclinical and clinical trial accruals |  | $ | 39,775 |  |  | $ | 44,113 |
Payroll and related accruals |  |  | 15,473 |  |  |  | 22,800 |
Contract liabilities to pharmaceutical distributors |  |  | 15,979 |  |  |  | 15,137 |
Accrued co-promotion expenses - current |  |  | 17,431 |  |  |  | 11,537 |
Roxadustat profit share to AstraZeneca |  |  | 7,007 |  |  |  | 7,007 |
Property taxes and other taxes |  |  | 9,242 |  |  |  | 5,970 |
Professional services |  |  | 5,948 |  |  |  | 4,869 |
Other |  |  | 8,926 |  |  |  | 8,088 |
Total accrued and other current liabilities |  | $ | 119,781 |  |  | $ | 119,521 |
Schedule of Other Long-term Liabilities | Other long-term liabilities consisted of the following (in thousands):
|  | March 31, 2021 |  |  | December 31, 2020 |
Accrued long-term co-promotion expenses |  | $ | 23,295 |  |  | $ | 27,424 |
Other long-term tax liabilities |  |  | 9,025 |  |  |  | 8,675 |
Operating lease liabilities, non-current |  |  | 3,354 |  |  |  | 853 |
Other |  |  | 2,661 |  |  |  | 2,690 |
Total other long-term liabilities |  | $ | 38,335 |  |  | $ | 39,642 |

X
- Definition Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of other noncurrent liabilities. + References No definition available. + Details
Name: | us-gaap_OtherNoncurrentLiabilitiesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 + Details
Name: | us-gaap_PropertyPlantAndEquipmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accrued liabilities. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of cash and cash equivalents. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766 + Details
Name: | us-gaap_ScheduleOfInventoryCurrentTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration